You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.


  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

Completion of Acquisition and Placing


("Alliance" or the "Group")

Completion of Acquisition and Placing, Re-admission and Director Shareholding

Alliance Pharma plc (AIM: APH) ("Alliance" or the "Company"), the specialty pharmaceutical company, today announces that the acquisition of the Healthcare Products Business from Sinclair IS Pharma plc (the "Acquisition") and the placing to part fund the Acquisition have completed and that the Company's enlarged issued share capital has been re-admitted to trading on AIM.

Accordingly, the Company now has 468,179,146 ordinary shares in issue and admitted to trading on AIM. Alliance does not hold any shares in treasury. This figure of 468,179,146 ordinary shares may be used by shareholders in the Company to determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Director Shareholding

The Company also announces that Andrew Smith, Non-executive Chairman of the Company, has purchased 75,000 ordinary shares in the Company at a price of 41 pence per share pursuant to the broker option exercised by Numis Securities Limited as announced on 3 December 2015. Following this transaction, Mr Smith's total beneficial interest in the Company is 275,000 ordinary shares representing 0.06% of the Company's issued share capital.

For further information:

Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer

Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black

Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar